Literature DB >> 21876330

Serous adenocarcinoma of the uterine cervix: a clinicopathological study of 12 cases and a review of the literature.

Shinichi Togami1, Takahiro Kasamatsu, Yuko Sasajima, Takashi Onda, Mitsuya Ishikawa, Shun-ichi Ikeda, Tomoyasu Kato, Hitoshi Tsuda.   

Abstract

BACKGROUND/AIMS: To determine the clinicopathological characteristics and potentially associated outcomes in patients diagnosed with serous adenocarcinoma of the uterine cervix.
METHODS: The records of surgically-treated patients with pathological stage pT1b-2b serous adenocarcinoma were reviewed.
RESULTS: Of 12 patients with serous adenocarcinoma who underwent radical hysterectomy, five had pT1b1N0 disease, two pT1b1N1, two pT1b2N0, and three pT2bN1. The 5-year overall survival rate for patients with or without parametrial involvement (pT2b vs. pT1b) was 0 and 89%, respectively. The 3-year recurrence-free survival rate for those with or without parametrial involvement was 33 and 89%, respectively. Four patients suffered recurrence, namely one of those who had pT1b (1/9, 11%) and 3 of those who had pT2b disease (100%). The sites of recurrence of pT2b disease were outside the pelvis in all 3 patients. Of these, 2 (67%) had peritoneal spread and 1 distant node metastasis.
CONCLUSION: While patients with pathological stage pT1b disease may have a relatively favorable outcome after radical surgery, those with more advanced disease have a poor prognosis because of extra-pelvic recurrence.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21876330     DOI: 10.1159/000329319

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  5 in total

Review 1.  The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix.

Authors:  Andres A Roma; Oluwole Fadare
Journal:  Virchows Arch       Date:  2018-02-05       Impact factor: 4.064

2.  Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.

Authors:  Shinichi Togami; Yuko Sasajima; Takahiro Kasamatsu; Rie Oda-Otomo; Satoshi Okada; Mitsuya Ishikawa; Shun-ichi Ikeda; Tomoyasu Kato; Hitoshi Tsuda
Journal:  Pathol Oncol Res       Date:  2014-11-05       Impact factor: 3.201

3.  The association between expression of p53 and aggressiveness of serous adenocarcinoma of the uterine cervix.

Authors:  Sul Lee; Hyun Joo Lee; Kyung Un Choi; Byung Su Kwon; Dong Soo Suh; Dae Hoon Jeong; Geun Joo Kim; Tae Hwa Lee; Hyun-Jin Roh; Ki Hyung Kim
Journal:  J Res Med Sci       Date:  2020-05-22       Impact factor: 1.852

4.  Serous carcinoma of the uterine cervix: Clinicopathological features differing from serous carcinomas of other female organs.

Authors:  Shoko Kitade; Kazuya Ariyoshi; Kenichi Taguchi; Shoji Maenohara; Yui Tomita; Kenzo Sonoda; Masao Okadome; Toshiaki Saito
Journal:  J Obstet Gynaecol Res       Date:  2019-10-22       Impact factor: 1.730

5.  So-Called Serous Carcinoma of the Uterine Cervix with BRCA2 Mutation: Case Report and Review of the Literature.

Authors:  Ruth Gabriela Herrera Gómez; Delfyne Hastir; Aikaterini Liapi; Ana Dolcan; Fernanda G Herrera; Patrice Mathevet; Apostolos Sarivalasis
Journal:  Case Rep Oncol       Date:  2021-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.